[Form 4] ANI Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

ANI Pharmaceuticals insider sale reported. Chad Gassert, SVP - Corporate Development & Strategy, reported a disposition of 20,000 shares of ANI Pharmaceuticals common stock on 08/15/2025 at a weighted-average price of $86.97 per share. Following the reported transactions, the reporting person beneficially owns 173,226 shares indirectly through Chali Properties LLC, over which he holds voting and dispositive power.

The filing clarifies the sale was executed in multiple trades at prices ranging from $86.54 to $88.05. The form is signed by an attorney-in-fact on behalf of Mr. Gassert and lists his role with the company as an officer.

Positive

• None.

Negative

• Officer sale of 20,000 shares disclosed at a weighted-average price of $86.97 on 08/15/2025
• Insider still holds voting and dispositive power over 173,226 shares indirectly, indicating retained control despite the disposition

Insights

Financial Analyst

Insider sold a modest block; watch position size relative to float.

The sale of 20,000 shares at a weighted-average price of $86.97 is a clear disposition but the filing shows the reporting person still beneficially controls 173,226 shares via an LLC. Without total outstanding shares or recent insider holdings history in this filing, the market impact is unclear. The execution across prices from $86.54 to $88.05 indicates the position was reduced in several trades rather than a single block sale.

Corporate Governance Expert

Transaction is routine disclosure of insider selling and retained indirect control.

The Form 4 documents an officer-level sale and confirms continued indirect ownership and voting/dispositive power through Chali Properties LLC. The filing includes the required explanation that the reported sale prices are a weighted average from multiple trades. There are no disclosures here of a 10b5-1 plan or other arrangements on the form itself.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gassert Chad

(Last) (First) (Middle)

C/O ANI PHARMACEUTICALS, INC.

210 MAIN STREET WEST

(Street)

BAUDETTE MN 56623

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP - CORP. DEV. & STRATEGY

3. Date of Earliest Transaction (Month/Day/Year)
08/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								73,615	D
Common Stock	08/15/2025		S		20,000	D	$86.97(1)	173,226	I	Held by Chali Properties LLC(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold in multiple trades at prices ranging from $86.54 to $88.05. The price reported above reflects the weighted average sales price.

2. The reporting person holds voting and dispositive power over the shares held by Chali Properties LLC.

Remarks:

	/s/ Chad Gassert, by attorney-in-fact Meredith W. Cook	08/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did ANI Pharmaceuticals (ANIP) insider Chad Gassert report on Form 4?

The filing reports a disposition of 20,000 shares on 08/15/2025 at a weighted-average price of $86.97, with 173,226 shares beneficially owned indirectly after the transaction.

At what prices were the ANIP shares sold by Chad Gassert?

The shares were sold in multiple trades at prices ranging from $86.54 to $88.05; the form reports the weighted-average sale price as $86.97.

Does Chad Gassert retain control of the sold shares after the transaction?

Yes. The filing states he holds voting and dispositive power over the shares held by Chali Properties LLC, which accounts for 173,226 shares after the reported transaction.

What is Chad Gassert's role at ANI Pharmaceuticals as listed on the Form 4?

He is listed as SVP - Corporate Development & Strategy and the filing is submitted as an individual Form 4 by one reporting person.

Was the sale executed under a 10b5-1 plan according to the Form 4?

The Form 4 does not indicate on its face that the transaction was executed pursuant to a 10b5-1 plan; no such plan is checked or described in this filing.